Multiple Sclerosis and the launch of Ocrevus
Slides in the pack:
- Multiple sclerosis (MS), the disease area
- MS affects Caucasians more than people of other races
- Greater prevalence of MS in higher northern and southern latitudes – with prevalence data
- Treatments for MS
- In March 2017, the FDA approved Ocrevus, the first drug to treat severe MS
- Phase III trial results for Ocrevus in relapsing-remitting MS
- Game-changing results with Ocrevus compensated for its severe side effects in the opinion of payers
- Recently launched or in-pipeline drugs that may emerge as threats to Ocrevus
Reviews
There are no reviews yet.